Press Releases Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-12-12 pm EST			5-day change	1st Jan Change
52.41 ^USD	+2.36%		+0.50%	-7.34%

Dec. 12	Morgan Stanley Adjusts Bristol-Myers Squibb PT to $37 From $36, Maintains Underweight Rating	MT
Dec. 12	Arcus scraps late-stage cancer trial after weak survival data	RE

Press Releases

U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo(R) (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma	Dec. 11	AQ
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma	Dec. 11	BU
Bristol Myers Squibb Announces Dividend Increase	Dec. 10	BU
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025	Dec. 08	BU
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)	Dec. 04	BU
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease	Dec. 03	BU
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio	Dec. 01	BU
Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference	Nov. 26	BU
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma	Nov. 24	BU
Bristol Myers Squibb to Host Hematology-Focused Investor Event	Nov. 24	BU
Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers	Nov. 18	BU
Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers	Nov. 17	BU
Update on Phase 3 Librexia ACS Trial	Nov. 14	BU
Bristol Myers Squibb Prices EUR5 Billion of Senior Unsecured Notes	Nov. 06	AQ
Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes	Nov. 05	BU
Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2025	Nov. 03	BU
Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes	Nov. 03	BU
Bristol Myers: Q3 Earnings Snapshot	Oct. 30	AQ
Bristol Myers Squibb : Q3 2025 Results Presentation (with Appendix)	Oct. 30	PU
Bristol Myers Squibb Reports Third Quarter Financial Results for 2025	Oct. 30	BU
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus	Oct. 28	AQ
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025	Oct. 27	AQ
Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus	Oct. 27	BU
Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025	Oct. 25	BU
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025	Oct. 17	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Technical Analysis: Bristol-Myers Squibb hesitates at a critical juncture

August 28, 2025 at 03:51 am EDT

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 12:53 pm EST